Established and emerging pharmacological therapies for post-myocardial infarction patients with heart failure: a review of the evidence

L De Luca - Cardiovascular Drugs and Therapy, 2020 - Springer
After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic
events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic …

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence.

L De Luca - Cardiovascular Drugs and Therapy, 2020 - europepmc.org
After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic
events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic …

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence

L De Luca - Cardiovascular drugs and therapy, 2020 - pubmed.ncbi.nlm.nih.gov
After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic
events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic …

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence

LL De - Cardiovascular Drugs and Therapy, 2020 - search.proquest.com
After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic
events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic …

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence.

L De Luca - Cardiovascular Drugs & Therapy, 2020 - search.ebscohost.com
After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic
events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic …